Moderate

Cystic fibrosis (paediatric)

respiratory · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Autosomal recessive CFTR disorder causing thick secretions, chronic suppurative lung disease, pancreatic insufficiency and salt loss. Most are detected by newborn screening; management is lifelong, multidisciplinary, and increasingly includes CFTR modulators.

Red flags

  • New Pseudomonas aeruginosa isolation (needs eradication therapy)
  • Haemoptysis or pneumothorax
  • Distal intestinal obstruction syndrome (DIOS)
  • Rapid lung function decline or faltering growth

Assessment

Differential diagnosis

  • Recurrent/chronic chest infection from other cause
  • Primary ciliary dyskinesia
  • Immunodeficiency
  • Coeliac disease (malabsorption/faltering growth)
  • Asthma with recurrent infection
  • Protracted bacterial bronchitis
  • Shwachman-Diamond syndrome

Investigations

  • Newborn blood spot (immunoreactive trypsinogen) then CFTR genetic testing
  • Sweat chloride test (diagnostic: elevated chloride)
  • Extended CFTR gene panel/sequencing
  • Faecal elastase (low in pancreatic insufficiency)
  • Respiratory cultures/cough swabs for Pseudomonas, Staph aureus, etc.
  • Baseline and serial spirometry, chest imaging, glucose tolerance and bone/liver surveillance

Management

  • Confirm diagnosis with sweat test and genotype after positive screening
  • Refer to a specialist CF multidisciplinary centre promptly
  • Start airway clearance physiotherapy and mucoactive agents
  • Begin pancreatic enzyme replacement and fat-soluble vitamin supplementation if insufficient
  • Optimise high-energy, high-salt nutrition and monitor growth closely
  • Treat respiratory infections aggressively and provide antibiotic prophylaxis per protocol
  • Commence CFTR modulator therapy where genotype-eligible
  • Monitor for complications (CF-related diabetes, liver disease, bone disease)
  • Ensure vaccinations, segregation to prevent cross-infection, and psychosocial support

Drugs & doses

Pancreatic enzyme replacement (Creon) ~2000-4000 units lipase per gram of dietary fat, titrated to stools/growth
Fat-soluble vitamins (A, D, E, K) daily supplementation
Dornase alfa 2.5 mg nebulised once daily (mucolytic)
Flucloxacillin prophylaxis ~12.5-25 mg/kg twice daily in young children; CFTR modulators (e.g. elexacaftor/tezacaftor/ivacaftor) for eligible genotypes

Disposition

Lifelong specialist CF centre care with shared-care; admit for exacerbations, DIOS, or acute deterioration.

Complications & pitfalls

  • Bronchiectasis and progressive respiratory failure
  • Pancreatic insufficiency, CF-related diabetes and liver disease
  • Distal intestinal obstruction syndrome and rectal prolapse
  • Osteoporosis, male infertility and salt-depletion crises

Exam pearls

  • Early Pseudomonas should be aggressively eradicated to delay chronic colonisation
  • Adequate enzyme dosing and high-calorie nutrition are central to outcome
  • CFTR modulators have transformed prognosis for eligible genotypes
  • Strict cross-infection control between CF patients is essential

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.